Biotricity Delivers Bioheart, A Groundbreaking Consumer Heart Monitor

Continuous monitoring device with advanced features and analytics to deliver personalized insights directly to the smartphone

Biotricity, Inc. (NASDAQ:BTCY), a modern medical technology company focused on delivering innovative, remote biometric monitoring solutions, today announced the availability of Bioheart, a direct-to-consumer heart monitor that offers the same continuous heart monitoring technology used by physicians. Showcased in prototype form at CES 2020, Bioheart has shipped to preorder customers and is now available for purchase at www.bioheart.com.

The launch of Bioheart opens a new market and revenue stream for Biotricity while expanding the company’s total addressable market by $1.24B, the global heart rate monitoring market. “Launching Bioheart and expanding into this new market is an important step for Biotricity and our ultimate goal of building a complete cardiac ecosystem to service individuals throughout their heart health journey,” said Dr. Waqaas Al-Siddiq, Founder and CEO of Biotricity.

Heart conditions are intermittent, requiring long term data collection for effective insights. With continuous monitoring, Bioheart reinvents personal heart management with retrospective snapshots. Introducing a groundbreaking new capability, users can create snapshots of rhythm data by reviewing past data and marking it for personal records. This is a first-of-its-kind feature that will help individuals look back at their data for a richer understanding of their lifestyle impact and heart health.

Bioheart features include:

With the Bioheart smartphone app, users can:

 
  • Built-in dry contacts for data collection
  • Advanced data collection – three different heart views
  • 24/7 continuous rhythm monitoring
  • 48 hour battery life
  • Personalized analytics
  • Bluetooth connected
  • View electrical heart rhythm live on the app
  • View data on advanced heart metrics such as electrical heart rhythm, heart rate and heart rate variability
  • View historical heart rate ranges
  • Create a heart rhythm diary and save snapshots of heart activity
  • Easily create retrospective snapshots, a first-of-its kind capability
  • Easily export and share heart data with a physician

Bioheart incorporates the Company’s proprietary advanced heart technology, combined with powerful analytics and continuous rhythm monitoring, to help individuals understand and improve their heart health. It provides 24/7 electrical heart rhythm monitoring and recording with three different views of the heart, which can be streamed live on the Bioheart smartphone app. Bioheart is the most accurate heart monitor available without a prescription.

“Bioheart combines unparalleled accuracy in a heart monitoring device with continuous data, advanced heart health insights, and powerful features tailored to individuals at risk for heart disease or who want precise data for performance tracking, optimization and preventative cardiac wellness,” said Dr. Al-Siddiq. “Bioheart furthers Biotricity’s mission of developing revolutionary healthcare solutions that help engage and empower individuals to take control of their health, starting with the deadliest chronic disease and one of healthcare’s largest cost drivers: cardiac disease.”

Heart condition signs are typically intermittent, and most heart monitoring devices only capture short periods of heart activity. These devices have limited capabilities and do not provide individuals with the heart data or tools needed to support preventative care and effective lifestyle improvements. With Bioheart’s continuous monitoring and long-term data collection approach, users can analyze heart data from previous months, well after the initial recording, to understand changes and long-term trends.

“Bioheart has the potential to make an immediate, life-changing impact for those who use it,” added Dr. Al-Siddiq. “As a direct manufacturer, we’re thrilled to have been able to accelerate our market delivery to the general market in less than a year, ahead of schedule and in time for the busy holiday gifting season.”

Bioheart retails for $199 and is available for purchase here or at www.bioheart.com. The app is available on Apple’s App Store and on Google Play.

You can see Bioheart in action here.

About Biotricity

Biotricity is reforming the healthcare market by bridging the gap in remote monitoring and chronic care management. Doctors and patients trust Biotricity’s unparalleled standard for preventive and personal care, including diagnostic and post-diagnostic solutions for chronic conditions. The company develops comprehensive remote health monitoring solutions for the medical and consumer markets. To learn more, visit www.biotricity.com.

Bioheart name, logo, and tag lines are trademarks of Biotricity Inc. US and International Patents Pending. Bioheart does not require a prescription.

Bioheart does not diagnose, treat, or repair heart disease. Bioheart is not intended to be a diagnostic tool, or for clinical use, or clinical interpretation, and is meant to be a lifestyle and wellness solution for individuals. If users of the Bioheart are concerned about the data obtained from the device, they should consult a medical professional directly for further advice. Biotricity disclaims any representation made, whether explicitly or implicitly, which would suggest the accuracy of the data obtained is suitable for clinical interpretation.

Bioheart as described herein, and subsequent versions, may or may not be the same as advertised and may or may not differ in features and functionality. Any statements made herein in relation to Bioheart, its features, functionality are based on design and concepts that the company believe are achievable, but the functionality may be different.

Important Cautions Regarding Forward-Looking Statements

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Forward-looking statements, which involve assumptions and describe our future plans, strategies, and expectations, are generally identifiable by use of the words “may,” “should,” “would,” “will,” “could,” “scheduled,” “expect,” “anticipate,” “estimate,” “believe,” “intend,” “seek,” “project,” or “goal” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements may include, without limitation, statements regarding (i) the plans, objectives and goals of management for future operations, including plans, objectives or goals relating to the design, development and commercialization of Bioflux, Bioheart, Biokit or any of the Company’s other proposed products or services, (ii) a projection of income (including income/loss), earnings (including earnings/loss) per share, capital expenditures, dividends, capital structure or other financial items, (iii) the Company's future financial performance, (iv) the regulatory regime in which the Company operates or intends to operate and (v) the assumptions underlying or relating to any statement described in points (i), (ii), (iii) or (iv) above. Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances and may not be realized because they are based upon the Company's current projections, plans, objectives, beliefs, expectations, estimates and assumptions and are subject to a number of risks and uncertainties and other influences, many of which the Company has no control over. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, the Company's inability to obtain additional financing, the significant length of time and resources associated with the development of its products and related insufficient cash flows and resulting illiquidity, the Company's inability to expand the Company's business, significant government regulation of medical devices and the healthcare industry, lack of product diversification, existing or increased competition, results of arbitration and litigation, stock volatility and illiquidity, and the Company's failure to implement the Company's business plans or strategies. These and other factors are identified and described in more detail in the Company's filings with the SEC. The Company assumes no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release.

Contacts

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.